Elizabeth Plimack, MD, MS, Talks Risk Categories in KEYNOTE-426 Trial on Advanced RCC
June 14th 2020Elizabeth Plimack, MD, MS, discussed the analysis of risk categories for patients included in the KEYNOTYE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.